PPARG and stroke disorder: For example, the synthetic PPARγ-activating compounds termed thiazolidinediones (e.g., pioglitazone, rosiglitazone) show evidence of ameliorating cerebral damage and neurological outcomes in animal models of cerebral ischemia as well as lowering recurrent stroke risk in stroke patients26–28.